Bevacizumab (DrugBank: Bevacizumab)
9 diseases| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 13 | 多発性硬化症／視神経脊髄炎 | 1 |
| 34 | 神経線維腫症 | 7 |
| 85 | 特発性間質性肺炎 | 2 |
| 86 | 肺動脈性肺高血圧症 | 1 |
| 87 | 肺静脈閉塞症／肺毛細血管腫症 | 1 |
| 89 | リンパ脈管筋腫症 | 1 |
| 227 | オスラー病 | 14 |
| 280 | 巨大動静脈奇形（頚部顔面又は四肢病変） | 1 |
| 331 | 特発性多中心性キャッスルマン病 | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01777412 (ClinicalTrials.gov) | June 2013 | 21/1/2013 | Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations | An Open-label Phase 1b Study of Avastin® (Bevacizumab) for the Treatment of Acute Optic Neuritis and/or Transverse Myelitis in Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD). | Neuromyelitis Optica;Neuromyelitis Optica Spectrum Disorder | Drug: Bevacizumab | Johns Hopkins University | Genentech, Inc.;Guthy Jackson Charitable Foundation | Completed | 18 Years | 70 Years | All | 10 | Phase 1 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-JapicCTI-194999 | 15/10/2019 | 14/10/2019 | BeatNF2 trial | A Randomized Double-blind Multicenter trial to Assess the Efficacy and Safety of Bevacizumab for Neurofibromatosis Type 2 | Neurofibromatosis type 2 | Intervention name : Bevacizumab (Genitical Recombination) INN of the intervention : Bevacizumab (Genitical Recombination) Dosage And administration of the intervention : 5mg/kg in a total volume of 100ml, div, every 2 week Control intervention name : Isotonic sodium chloride solution INN of the control intervention : - Dosage And administration of the control intervention : 100ml, div | Kiyoshi Saito | Masazumi Fujii, Masao Kobayakawa, Akihiro Inano, Jun Sakuma, Taku Sato, Akio Morita, Mitsuhiro Hasegawa, Takafumi Mitsuhara, Takashi Tamiya, Takeo Goro, Shigeru Yamaguchi, Hirofumi Nakatomi, Soichi Oya | pending | 18 | 64 | BOTH | 60 | Phase 2 | Japan |
| 2 | ChiCTR1800016040 | 2018-05-09 | 2018-05-08 | Clinical efficacy of Bevacizumab in the treatment of Type II Neurofibromatosis | Clinical efficacy of Bevacizumab in the treatment of Type II Neurofibromatosis | Type II Neurofibromatosis | Case series:Bevacizumab therapy; | Shanghai Ninth People's Hospital affiliated to Shanghai JiaoTong University, School of Medicine | NULL | Recruiting | 6 | Both | Case series:30; | China | ||
| 3 | NCT01767792 (ClinicalTrials.gov) | May 15, 2013 | 7/1/2013 | Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas | Open-label, Phase 2 Study of Bevacizumab in Children and Young Adults With Neurofibromatosis 2 and Progressive Vestibular Schwannomas That Are Poor Candidates for Standard Treatment With Surgery or Radiation | Neurofibromatosis Type 2;Progressive Vestibular Schwannomas | Drug: Bevacizumab | University of Alabama at Birmingham | Genentech, Inc. | Active, not recruiting | 6 Years | N/A | All | 22 | Phase 2 | United States |
| 4 | NCT01661283 (ClinicalTrials.gov) | September 2012 | 7/8/2012 | SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors | Phase 2 Study of the mTOR Inhibitor Everolimus in Combination With Bevacizumab in Patients With Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors | Malignant Peripheral Nerve Sheath Tumors;MPNST;Sarcoma | Drug: everolimus;Drug: bevacizumab | Sarcoma Alliance for Research through Collaboration | Novartis Pharmaceuticals;Genentech, Inc.;United States Department of Defense | Completed | 18 Years | N/A | All | 25 | Phase 2 | United States |
| 5 | NCT01552434 (ClinicalTrials.gov) | March 16, 2012 | 7/3/2012 | Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease | A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other Indications | Advanced Malignant Neoplasm;Castleman Disease;Digestive System Carcinoma;Erdheim-Chester Disease;Lip and Oral Cavity Carcinoma;Lymphangioleiomyomatosis;Malignant Endocrine Neoplasm;Malignant Female Reproductive System Neoplasm;Malignant Male Reproductive System Neoplasm;Malignant Neoplasm;Malignant Respiratory Tract Neoplasm;Malignant Thoracic Neoplasm;Malignant Urinary System Neoplasm;Mesothelial Neoplasm;Metastatic Malignant Neoplasm;Metastatic Urothelial Carcinoma;Neurofibromatosis Type 2;Recurrent Adult Soft Tissue Sarcoma;Recurrent Breast Carcinoma;Recurrent Childhood Soft Tissue Sarcoma;Recurrent Digestive System Carcinoma;Recurrent Female Reproductive System Carcinoma;Recurrent Male Reproductive System Carcinoma;Recurrent Malignant Neoplasm;Recurrent Pharyngeal Carcinoma;Recurrent Thyroid Gland Carcinoma;Refractory Malignant Neoplasm;Soft Tissue Neoplasm;Stage III Breast Cancer AJCC v7;Stage III Pharyngeal Cancer;Stage IIIA Breast Cancer AJCC v7;Stage IIIB Breast Cancer AJCC v7;Stage IIIC Breast Cancer AJCC v7;Stage IV Breast Cancer AJCC v6 and v7;Stage IV Pharyngeal Cancer;Stage IVA Pharyngeal Cancer;Stage IVB Pharyngeal Cancer;Stage IVC Pharyngeal Cancer;Thyroid Gland Neoplasm | Biological: Bevacizumab;Biological: Cetuximab;Other: Laboratory Biomarker Analysis;Other: Pharmacological Study;Drug: Temsirolimus;Drug: Valproic Acid | M.D. Anderson Cancer Center | National Cancer Institute (NCI) | Recruiting | N/A | N/A | All | 216 | Phase 1 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT01207687 (ClinicalTrials.gov) | October 2010 | 1/9/2010 | Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) | Phase 2 Study of Bevacizumab in Children and Adults With Neurofibromatosis Type 2 and Symptomatic Vestibular Schwannoma | Vestibular Schwannoma;Neurofibromatosis Type 2 | Biological: bevacizumab;Other: laboratory biomarker analysis;Procedure: quality-of-life assessment | National Cancer Institute (NCI) | NULL | Completed | 12 Years | N/A | All | 14 | Phase 2 | United States |
| 7 | NCT01125046 (ClinicalTrials.gov) | July 2010 | 7/5/2010 | Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas | Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas | Acoustic Schwannoma;Adult Anaplastic Meningioma;Adult Ependymoma;Adult Grade I Meningioma;Adult Grade II Meningioma;Adult Meningeal Hemangiopericytoma;Adult Papillary Meningioma;Neurofibromatosis Type 1;Neurofibromatosis Type 2;Recurrent Adult Brain Tumor | Biological: bevacizumab | Northwestern University | NULL | Unknown status | 18 Years | N/A | All | 50 | Phase 2 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-jRCTs061180046 | 17/01/2013 | 12/03/2019 | CBDCA, PTX and BV for NSCLC (non-sq) with IP | Phase II study of carboplatin, weekly paclitaxel and bevacizumab for advanced non-squamous cell, non-small-cell lung cancer with idiopathic interstitial pneumonia - IP002 | Non-squamous, non-small cell lung cancer Lung cancer | Carboplatin (AUC=5) given on day1, paclitaxel (70mg/m2) given on days 1,8,15 and bevacizumab (15mg/m2) on day 1 every 4weeks until disease progression or unmanageable toxicity. | Katakami Nobuyuki | NULL | Not Recruiting | >= 20age old | Not applicable | Both | 35 | Phase 2 | Japan |
| 2 | JPRN-UMIN000018322 | 2012/12/01 | 15/07/2015 | Phase II study of carboplatin, weekly paclitaxel and bevacizumab for advanced non-squamous cell, non-small-cell lung cancer with idiopathic interstitial pneumonia | advanced non-squamous cell, non-small-cell lung cancer with idiopathic interstitial pneumonia | carboplatin AUC = 5, day1 paclitaxel 70mg/m2, day1 ,8 ,15 bevacizumab 15mg/kg, day1 every 4 weeks, 4-6 cycle | IP lung cancer study group | NULL | Recruiting | 20years-old | Not applicable | Male and Female | 35 | Phase 2 | Japan |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03166306 (ClinicalTrials.gov) | May 1, 2018 | 9/5/2017 | Angiogenic Imaging in Pulmonary Arterial Hypertension | Angiogenic Imaging in Pulmonary Arterial Hypertension | Pulmonary Arterial Hypertension;Exercise Associated Pulmonary Arterial Hypertension | Diagnostic Test: PET-CT Imaging with [89Zr]-bevacizumab | Brigham and Women's Hospital | NULL | Unknown status | 18 Years | N/A | All | 30 | Phase 1;Phase 2 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00891527 (ClinicalTrials.gov) | October 2008 | 30/4/2009 | Pilot Study Using Avastin and Gleevec to Treat the Progression of Intraluminal Pulmonary Vein Stenosis | Adjunct Targeted Biologic Inhibition in Children With Multivessel Intraluminal Pulmonary Vein Stenosis | Pulmonary Veno Occlusive Disease | Drug: Bevacizumab (Avastin) and Imatinib Mesylate (Gleevec) | Boston Children's Hospital | NULL | Completed | N/A | N/A | All | 50 | Phase 1;Phase 2 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01552434 (ClinicalTrials.gov) | March 16, 2012 | 7/3/2012 | Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease | A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other Indications | Advanced Malignant Neoplasm;Castleman Disease;Digestive System Carcinoma;Erdheim-Chester Disease;Lip and Oral Cavity Carcinoma;Lymphangioleiomyomatosis;Malignant Endocrine Neoplasm;Malignant Female Reproductive System Neoplasm;Malignant Male Reproductive System Neoplasm;Malignant Neoplasm;Malignant Respiratory Tract Neoplasm;Malignant Thoracic Neoplasm;Malignant Urinary System Neoplasm;Mesothelial Neoplasm;Metastatic Malignant Neoplasm;Metastatic Urothelial Carcinoma;Neurofibromatosis Type 2;Recurrent Adult Soft Tissue Sarcoma;Recurrent Breast Carcinoma;Recurrent Childhood Soft Tissue Sarcoma;Recurrent Digestive System Carcinoma;Recurrent Female Reproductive System Carcinoma;Recurrent Male Reproductive System Carcinoma;Recurrent Malignant Neoplasm;Recurrent Pharyngeal Carcinoma;Recurrent Thyroid Gland Carcinoma;Refractory Malignant Neoplasm;Soft Tissue Neoplasm;Stage III Breast Cancer AJCC v7;Stage III Pharyngeal Cancer;Stage IIIA Breast Cancer AJCC v7;Stage IIIB Breast Cancer AJCC v7;Stage IIIC Breast Cancer AJCC v7;Stage IV Breast Cancer AJCC v6 and v7;Stage IV Pharyngeal Cancer;Stage IVA Pharyngeal Cancer;Stage IVB Pharyngeal Cancer;Stage IVC Pharyngeal Cancer;Thyroid Gland Neoplasm | Biological: Bevacizumab;Biological: Cetuximab;Other: Laboratory Biomarker Analysis;Other: Pharmacological Study;Drug: Temsirolimus;Drug: Valproic Acid | M.D. Anderson Cancer Center | National Cancer Institute (NCI) | Recruiting | N/A | N/A | All | 216 | Phase 1 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04404881 (ClinicalTrials.gov) | May 2020 | 22/5/2020 | Bevacizumab In Hereditary Hemorrhagic Telangiectasia | A Phase 2 Study of Bevacizumab for Chronic Bleeding and Iron Deficiency Anemia in Hereditary Hemorrhagic Telangiectasia | Hereditary Hemorrhagic Telangiectasia | Drug: Bevacizumab | Hanny Al-Samkari, MD | NULL | Not yet recruiting | 18 Years | N/A | All | 20 | Phase 2 | United States |
| 2 | EUCTR2017-001031-39-FR (EUCTR) | 19/05/2017 | 19/06/2020 | BABH Study: Efficacy and safety of bevacizumab on severe bleedings associated with Hemorrhagic Hereditary Telangiectasia (HHT) | BABH Study: Efficacy and safety of bevacizumab on severe bleedings associated with Hemorrhagic Hereditary Telangiectasia (HHT). A National, randomized multicenter phase III study. - BABH | Hemorrhagic Hereditary Telangiectasia MedDRA version: 20.0;Level: LLT;Classification code 10031132;Term: Osler-Weber-Rendu disease;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Trade Name: AVASTIN Product Name: BEVACIZUMAB INN or Proposed INN: BEVACIZUMAB | Hospices Civils de Lyon | NULL | Not Recruiting | Female: yes Male: yes | 24 | Phase 3 | France | ||
| 3 | NCT02157987 (ClinicalTrials.gov) | December 15, 2014 | 4/6/2014 | Treatment of Hereditary Hemorrhagic Telangiectasia of the Nasal Mucosa by Intranasal Bevacizumab : Search for Effective Dose | Treatment of Hereditary Hemorrhagic Telangiectasia of the Nasal Mucosa by Intranasal Bevacizumab : Search for Effective Dose | Telangiectasia, Hereditary Hemorrhagic | Drug: bevacuzimab spray | University Hospital, Caen | NULL | Recruiting | 18 Years | 70 Years | All | 30 | Phase 1;Phase 2 | France |
| 4 | NCT02389959 (ClinicalTrials.gov) | August 4, 2014 | 11/3/2015 | Intranasal Bevacizumab for HHT-Related Epistaxis | Intranasal Bevacizumab for HHT-Related Epistaxis | HHT;Hereditary Hemorrhagic Telangiectasia;Epistaxis;Nose Bleeds;Nasal Bleeding | Drug: Bevacizumab;Drug: Placebo (Saline) | Stanford University | NULL | Completed | 18 Years | N/A | All | 40 | Phase 4 | United States |
| 5 | NCT02106520 (ClinicalTrials.gov) | April 2014 | 1/4/2014 | Efficacy of a Bevacizumab Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) | Efficacy of a Bevacizumab Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) | Hereditary Hemorrhagic Telangiectasia;Epistaxis | Drug: Bevacizumab;Drug: placebo | Hospices Civils de Lyon | NULL | Terminated | 18 Years | N/A | Both | 80 | Phase 2;Phase 3 | France |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | EUCTR2013-004204-19-FR (EUCTR) | 26/02/2014 | 16/06/2015 | Efficacité du bevacizumab en spray nasal pour le traitement des épistaxis dans la maladie de Rendu-Osler | Efficacité du bevacizumab en spray nasal pour le traitement des épistaxis dans la maladie de Rendu-Osler - ALEGORI | Rendu-Osler disease MedDRA version: 18.0;Level: LLT;Classification code 10031132;Term: Osler-Weber-Rendu disease;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Trade Name: Avastin Product Name: Avastin INN or Proposed INN: BEVACIZUMAB | Hospices Civils de Lyon | NULL | Not Recruiting | Female: yes Male: yes | France | ||||
| 7 | NCT01507480 (ClinicalTrials.gov) | October 2011 | 6/12/2011 | The ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of Bevacizumab Nasal Spray to Treat Epistaxis in Hereditary Hemorrhagic Telangiectasia | The ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of Bevacizumab Nasal Spray to Treat Epistaxis in Hereditary Hemorrhagic Telangiectasia. | Hemorrhagic Hereditary Telangiectasia | Drug: Bevacizumab | Hospices Civils de Lyon | NULL | Completed | 18 Years | N/A | Both | 42 | Phase 1 | France |
| 8 | NCT01408030 (ClinicalTrials.gov) | August 2011 | 1/8/2011 | North American Study of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) | North American Study of Epistaxis in HHT (NOSE) | Telangiectasia, Hereditary Hemorrhagic;Epistaxis | Drug: Sterile saline;Drug: Bevacizumab;Drug: Estriol;Drug: Tranexamic Acid | James Gossage | HHT Foundation International | Completed | 18 Years | N/A | All | 123 | Phase 2 | United States |
| 9 | NCT01314274 (ClinicalTrials.gov) | March 2011 | 9/3/2011 | Intranasal Submucosal Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) | A Randomized Double Blind Placebo Controlled Trial of Intranasal Submucosal Bevacizumab in Hereditary Hemorrhagic Telangiectasia | HHT;Morbus Osler;Epistaxis | Drug: Bevacizumab;Drug: NaCl | Medical University of Vienna | NULL | Completed | 18 Years | 80 Years | Both | 15 | Phase 2 | Austria |
| 10 | EUCTR2009-018049-19-AT (EUCTR) | 13/12/2010 | 23/11/2010 | A randomized double blind placebo controlled trial of intranasal submucosal bevacizumab in hereditary hemorrhagic telangiectasia - Bevazizumab in HHT | A randomized double blind placebo controlled trial of intranasal submucosal bevacizumab in hereditary hemorrhagic telangiectasia - Bevazizumab in HHT | epistaxis | Trade Name: AVASTIN 25 mg/ml - Konzentrat zur Herstellung einer Infusionsloesung INN or Proposed INN: BEVACIZUMAB Trade Name: PHYSIOLOGISCHE Kochsalzloesung Fresenius - Infusionsloesung Product Name: PHYSIOLOGISCHE Kochsalzloesung Fresenius - Infusionsloesung Other descriptive name: SODIUM CHLORIDE | Medizinische Universität Wien,Univ.Klinik f.Hals-, Nasen- und Ohrenkrankheiten | NULL | Not Recruiting | Female: yes Male: yes | 30 | Austria | |||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | NCT01402531 (ClinicalTrials.gov) | July 22, 2010 | 19/7/2011 | Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) | Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) | Hereditary Hemorrhagic Telangiectasia (HHT) | Drug: Submucosal Bevacizumab | University of California, San Diego | NULL | Completed | 18 Years | N/A | All | 10 | Phase 2 | United States |
| 12 | NCT01397695 (ClinicalTrials.gov) | June 2009 | 18/7/2011 | Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) | Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) | Hereditary Hemorrhagic Telangiectasia (HHT) | Drug: Bevacizumab | University of California, San Diego | NULL | Completed | 18 Years | N/A | All | 20 | Phase 2 | United States |
| 13 | EUCTR2008-006755-44-FR (EUCTR) | 15/01/2009 | 17/03/2009 | METAFORE : Maladie de Rendu-Osler : Etude de l’Efficacité et de la tolérance du Bevacizumab utilisé pour le traitement des formes hépatiques sévères. Etude de phase II - METAFORE | METAFORE : Maladie de Rendu-Osler : Etude de l’Efficacité et de la tolérance du Bevacizumab utilisé pour le traitement des formes hépatiques sévères. Etude de phase II - METAFORE | Maladie de Rendu-Osler MedDRA version: 9.1;Level: LLT;Classification code 10031132;Term: Osler-Weber-Rendu disease | Trade Name: AVASTIN Product Name: AVASTIN INN or Proposed INN: BEVACIZUMAB Other descriptive name: SUB16402MIG | HOSPICES CIVILS DE LYON | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Phase 2 | France | |||
| 14 | EUCTR2010-020545-26-IT (EUCTR) | 09/12/2008 | 10/09/2010 | BEVACIZUMAB, AN ANTI-ANGIOGENIC MONOCLONAL ANTIBODY EFFECTIVE FOR PREVENTION OF HEMORRHAGING IN PATIENTS WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT): POSSIBLE REGRESSION OF VISCERAL ARTERIOVENOUS MALFORMATIONS - ND | BEVACIZUMAB, AN ANTI-ANGIOGENIC MONOCLONAL ANTIBODY EFFECTIVE FOR PREVENTION OF HEMORRHAGING IN PATIENTS WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT): POSSIBLE REGRESSION OF VISCERAL ARTERIOVENOUS MALFORMATIONS - ND | HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT) MedDRA version: 9.1;Level: SOC;Classification code 10005329 | Trade Name: AVASTIN INN or Proposed INN: Bevacizumab Trade Name: AVASTIN INN or Proposed INN: Bevacizumab Trade Name: AVASTIN INN or Proposed INN: Bevacizumab | AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Italy |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02314377 (ClinicalTrials.gov) | June 2016 | 25/11/2014 | Bevacizumab Therapy for Brain Arteriovenous Malformation | Bevacizumab Therapy for Brain Arteriovenous Malformation | Brain Arteriovenous Malformation | Drug: Bevacizumab | University of California, San Francisco | NULL | Completed | 18 Years | 64 Years | All | 2 | Phase 1 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01552434 (ClinicalTrials.gov) | March 16, 2012 | 7/3/2012 | Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease | A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other Indications | Advanced Malignant Neoplasm;Castleman Disease;Digestive System Carcinoma;Erdheim-Chester Disease;Lip and Oral Cavity Carcinoma;Lymphangioleiomyomatosis;Malignant Endocrine Neoplasm;Malignant Female Reproductive System Neoplasm;Malignant Male Reproductive System Neoplasm;Malignant Neoplasm;Malignant Respiratory Tract Neoplasm;Malignant Thoracic Neoplasm;Malignant Urinary System Neoplasm;Mesothelial Neoplasm;Metastatic Malignant Neoplasm;Metastatic Urothelial Carcinoma;Neurofibromatosis Type 2;Recurrent Adult Soft Tissue Sarcoma;Recurrent Breast Carcinoma;Recurrent Childhood Soft Tissue Sarcoma;Recurrent Digestive System Carcinoma;Recurrent Female Reproductive System Carcinoma;Recurrent Male Reproductive System Carcinoma;Recurrent Malignant Neoplasm;Recurrent Pharyngeal Carcinoma;Recurrent Thyroid Gland Carcinoma;Refractory Malignant Neoplasm;Soft Tissue Neoplasm;Stage III Breast Cancer AJCC v7;Stage III Pharyngeal Cancer;Stage IIIA Breast Cancer AJCC v7;Stage IIIB Breast Cancer AJCC v7;Stage IIIC Breast Cancer AJCC v7;Stage IV Breast Cancer AJCC v6 and v7;Stage IV Pharyngeal Cancer;Stage IVA Pharyngeal Cancer;Stage IVB Pharyngeal Cancer;Stage IVC Pharyngeal Cancer;Thyroid Gland Neoplasm | Biological: Bevacizumab;Biological: Cetuximab;Other: Laboratory Biomarker Analysis;Other: Pharmacological Study;Drug: Temsirolimus;Drug: Valproic Acid | M.D. Anderson Cancer Center | National Cancer Institute (NCI) | Recruiting | N/A | N/A | All | 216 | Phase 1 | United States |